☆ 4.6 Article

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Acute subjective effects in LSD- and MDMA-assisted psychotherapy

Yasmin Schmid et al.

Summary: The study described patient characteristics, treatment indications and acute alterations of mind in patients receiving LSD and/or MDMA in the Swiss compassionate use programme. LSD induced pronounced alterations of consciousness and mystical-type experiences, with increases in all scales on the Mystical Experience Questionnaire. The effects were largely comparable between patients in the compassionate use programme and patients or healthy subjects in a research setting.

JOURNAL OF PSYCHOPHARMACOLOGY (2021)

Add to Collection

Article Neurosciences

Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects

Friederike Holze et al.

Summary: This study evaluated the subjective and autonomic effects of different doses of LSD in healthy subjects. It found that LSD displayed dose-proportional pharmacokinetics and dose-dependently induced subjective responses, with a ceiling effect observed for good drug effects at 100 μg. The results suggest that future LSD research may benefit from dose finding based on these findings, and that the full psychedelic effects of LSD are primarily mediated by serotonin 5-HT2A receptor activation.

NEUROPSYCHOPHARMACOLOGY (2021)

Add to Collection

Article Neurosciences

Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy

Allison A. Feduccia et al.

Summary: This study aimed to explore the impact of tapering antidepressant medications on the effectiveness of MDMA-assisted psychotherapy. The results showed that the non-taper group had significantly lower CAPS-IV total scores at the primary endpoint, with more participants in this group no longer meeting PTSD criteria. Additionally, the non-taper group had lower depression symptom severity scores compared to the taper group.

PSYCHOPHARMACOLOGY (2021)

Add to Collection

Article Biochemical Research Methods

Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin ' s main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma

Karolina E. Kolaczynska et al.

Summary: A rapid LC-MS/MS method was developed and validated for quantifying psilocin and its metabolite 4-HIAA in human plasma, showing good accuracy and precision over three validation runs. This method could assess the pharmacokinetics of psilocin and 4-HIAA and facilitate the clinical development of psilocybin.

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2021)

Add to Collection

Article Clinical Neurology

Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches

Albert Garcia-Romeu et al.

Summary: The study found that the subjective effects of psilocybin were not affected by body weight when administered either on a weight-adjusted basis or as a fixed dose. The convenience and lower cost of administering psilocybin as a fixed dose outweigh any potential advantages of weight-adjusted dosing.

JOURNAL OF PSYCHOPHARMACOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Psychedelic-inspired drug discovery using an engineered biosensor

Chunyang Dong et al.

Summary: The study introduces psychLight, a genetically encoded fluorescent sensor based on the structure of 5-HT2AR, which can detect behaviorally relevant serotonin release and predict the effects of different 5-HT2AR ligands. This new technology identified a non-hallucinogenic psychedelic analog with rapid-onset and long-lasting antidepressant-like effects.

CELL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

Jennifer M. Mitchell et al.

Summary: The results demonstrate that MDMA-assisted therapy is safe and effective in treating severe post-traumatic stress disorder. Compared with placebo, MDMA significantly reduces CAPS-5 scores and improves functional impairment.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Trial of Psilocybin versus Escitalopram for Depression

Robin Carhart-Harris et al.

Summary: The study compared the efficacy of psilocybin and escitalopram in treating patients with major depressive disorder. While there was no significant difference in antidepressant effects between the two drugs at week 6, secondary outcomes generally favored psilocybin over escitalopram, though these results were not adjusted for multiple comparisons. Larger and longer trials are needed to further compare psilocybin with established antidepressants.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Psychiatry

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder A Randomized Clinical Trial

Alan K. Davis et al.

Summary: The study showed that psilocybin therapy with psychological support is effective in treating MDD, building on previous findings in patients with cancer and depression, as well as in a nonrandomized study in patients with treatment-resistant depression.

JAMA PSYCHIATRY (2021)

Add to Collection

Article Chemistry, Medicinal

Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers

Nadia R. P. W. Hutten et al.

Summary: The study found that single low doses of LSD can significantly increase BDNF levels in healthy volunteers in a short period of time, providing a new direction for researching the use of LSD in patient populations.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2021)

Add to Collection

Article Pharmacology & Pharmacy

Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin/Psilocin

Elyes Dahmane et al.

Summary: The study assessed the potential proarrhythmic effect of psilocin and found a significant but shallow relationship between concentration-QTc interval. At clinical doses, the QTcF change was small and there was no accumulation of psilocin after monthly oral doses in trials.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2021)

Add to Collection

Article Neurosciences

Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects

Friederike Holze et al.

NEUROPSYCHOPHARMACOLOGY (2020)

Add to Collection

Review Neurosciences

The Role of BDNF on Neural Plasticity in Depression

Yang Tao et al.

FRONTIERS IN CELLULAR NEUROSCIENCE (2020)

Add to Collection

Article Behavioral Sciences

Changes in brain metabolites related to stress resilience: Metabolomic analysis of the hippocampus in a rat model of depression

Hayato Akimoto et al.

BEHAVIOURAL BRAIN RESEARCH (2019)

Add to Collection

Article Pharmacology & Pharmacy

Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects

Friederike Holze et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)

Add to Collection

Article Psychology, Multidisciplinary

Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial

Raissa Nobrega de Almeida et al.

FRONTIERS IN PSYCHOLOGY (2019)

Add to Collection

Article Neurosciences

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

R. L. Carhart-Harris et al.

PSYCHOPHARMACOLOGY (2018)

Add to Collection

Article Cell Biology

Psychedelics Promote Structural and Functional Neural Plasticity

Calvin Ly et al.

CELL REPORTS (2018)

Add to Collection

Article Pharmacology & Pharmacy

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression

Leor Roseman et al.

FRONTIERS IN PHARMACOLOGY (2018)

Add to Collection

Article Pharmacology & Pharmacy

Predicting Responses to Psychedelics: A Prospective Study

Eline C. H. M. Haijen et al.

FRONTIERS IN PHARMACOLOGY (2018)

Add to Collection

Article Neurosciences

Alterations of consciousness and mystical-type experiences after acute LSD in humans

Matthias E. Liechti et al.

PSYCHOPHARMACOLOGY (2017)

Add to Collection

Review Psychiatry

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Chiara Fabbri et al.

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2017)

Add to Collection

Article Clinical Neurology

Escitalopram plasma levels and antidepressant response

Vincenzo Florio et al.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2017)

Add to Collection

Article Pharmacology & Pharmacy

Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults

Randall T. Brown et al.

CLINICAL PHARMACOKINETICS (2017)

Add to Collection

Article Clinical Neurology

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens

Anna Rickli et al.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2016)

Add to Collection

Article Clinical Neurology

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

Roland R. Griffiths et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2016)

Add to Collection

Article Clinical Neurology

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

Stephen Ross et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2016)

Add to Collection

Article Psychiatry

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Robin L. Carhart-Harris et al.

LANCET PSYCHIATRY (2016)

Add to Collection

Article Neurosciences

Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects

Yasmin Schmid et al.

BIOLOGICAL PSYCHIATRY (2015)

Add to Collection

Article Clinical Neurology

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Frederick S. Barrett et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2015)

Add to Collection

Article Clinical Neurology

Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases

Peter Gasser et al.

JOURNAL OF NERVOUS AND MENTAL DISEASE (2014)

Add to Collection

Article Multidisciplinary Sciences

Prediction of Psilocybin Response in Healthy Volunteers

Erich Studerus et al.

PLOS ONE (2012)

Add to Collection

Article Clinical Neurology

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies

Erich Studerus et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2011)

Add to Collection

Article Neurosciences

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Roland R. Griffiths et al.

PSYCHOPHARMACOLOGY (2011)

Add to Collection

Article Emergency Medicine

Effects of a β-blocker on the cardiovascular response to MDMA (Ecstasy)

C. M. Hysek et al.

EMERGENCY MEDICINE JOURNAL (2010)

Add to Collection

Article Psychiatry

Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression

Raoul Belzeaux et al.

JOURNAL OF PSYCHIATRIC RESEARCH (2010)

Add to Collection

Article Multidisciplinary Sciences

Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV)

Erich Studerus et al.

PLOS ONE (2010)

Add to Collection

Article Neurosciences

Gene Expression as Peripheral Biomarkers for Sporadic Alzheimer's Disease

Edna Gruenblatt et al.

JOURNAL OF ALZHEIMERS DISEASE (2009)

Add to Collection

Review Clinical Neurology

Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression

Jun-ichi Iga et al.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2007)

Add to Collection

Article Neurosciences

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

R. R. Griffiths et al.

PSYCHOPHARMACOLOGY (2006)

Add to Collection

Article Psychiatry

The effect of paroxetine on 5-HT2A receptors in depression: An [F-18]setoperone PET imaging study

JH Meyer et al.

AMERICAN JOURNAL OF PSYCHIATRY (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.